BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 37713790)

  • 1. Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.
    Zhang J; Liu Y; Xia L; Zhen J; Gao J; Atsushi T
    Comput Biol Med; 2023 Oct; 165():107459. PubMed ID: 37713790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma.
    Li S; Wang Y; Sun R; Franceschi D; Pan H; Wei C; Ogbuehi AC; Lethaus B; Savkovic V; Gaus S; Zimmerer R; Ziebolz D; Schmalz G; Jiang X
    J Immunol Res; 2022; 2022():2079389. PubMed ID: 36157879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
    Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
    J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
    Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
    BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
    Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
    BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
    Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
    Front Immunol; 2021; 12():791621. PubMed ID: 35003112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtyping of head and neck squamous cell cancers based on immune signatures.
    Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
    Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy.
    Wang W; Zhang Z; Li W; Wei D; Xu J; Qian Y; Cao S; Lei D
    Aging (Albany NY); 2023 Nov; 15(21):12588-12617. PubMed ID: 37955651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of
    Zhang P; Zhao Y; Xia X; Mei S; Huang Y; Zhu Y; Yu S; Chen X
    Oncoimmunology; 2023; 12(1):2203073. PubMed ID: 37089448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
    Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
    Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of two distinct head and neck squamous cell carcinoma subtypes based on fatty acid metabolism-related signatures: Implications for immunotherapy and chemotherapy.
    Zou J; Dai Y; Xu G; Kai Y; Lan L; Zhang J; Wang Y
    Medicine (Baltimore); 2024 Apr; 103(16):e37824. PubMed ID: 38640298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
    Baysal H; Siozopoulou V; Zaryouh H; Hermans C; Lau HW; Lambrechts H; Fransen E; De Pauw I; Jacobs J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; De Waele J; Wouters A
    Front Immunol; 2022; 13():1001161. PubMed ID: 36268020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
    Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
    Front Immunol; 2021; 12():757047. PubMed ID: 34675936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    Shi Y; Huang J; Hu Y; Shen Y
    BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic model based on Scissor
    Tian G; Zhang J; Bao Y; Li Q; Hou J
    Cell Signal; 2024 Feb; 114():110984. PubMed ID: 38029947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.
    Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q
    Front Immunol; 2024; 15():1364082. PubMed ID: 38562924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The head and neck cancer immune landscape and its immunotherapeutic implications.
    Mandal R; Şenbabaoğlu Y; Desrichard A; Havel JJ; Dalin MG; Riaz N; Lee KW; Ganly I; Hakimi AA; Chan TA; Morris LG
    JCI Insight; 2016 Oct; 1(17):e89829. PubMed ID: 27777979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.